Recent Developments in Pharmacological Effect, Mechanism and Application Prospect of Diazeniumdiolates

Bin Li, Yue Ming, Yao Liu, Haiyan Xing, Ruoqiu Fu, Ziwei Li, Rui Ni, Li Li, Dongyu Duan, Jing Xu, Chen Li, Mingfeng Xiang, Hongyu Song and Jianhong Chen*

Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, China

Nitric oxide (NO) is a simple structured and unstable free radical molecule, which participates in the regulation of many pathophysiological processes. It functions both as a second messenger and as an endogenous neurotransmitter. Diazeniumdiolates (NONOates) are a series of compounds containing the functional parent nuclear structure of [N(O)NO]−, which are the most widely studied NO donors. NONOates are unstable and easy to release NO in physiological conditions. The biomedical applications and drug development of NO donor have attracted the scientists’ attention in recent years. In this review, recent advances in NONOates research are highlighted in terms of chemical structures, molecular characteristics, pharmacological effects, and biomedical application prospects.

Keywords: diazeniumdiolates, structure, characteristics, pharmacological effect, application prospect

INTRODUCTION

Nitric oxide (NO) is a simple and unstable free radical, which is considered as a versatile endogenous molecule and a crucial signaling factor in many biochemistry and physiological pathways. NO participates in such pathophysiological processes as vasodilation, signaling, and endocrine regulation (Heckler and Boon, 2019). On the one hand, depletion of NO or attenuation of its effector system may result in hypertension, angina and impotence. On the other hand, the overproduction of NO may cause many damages, such as circulatory shock, sepsis, neurodegenerative disorders and inflammatory responses (Stroppel et al., 2018; Spiller et al., 2019). NO can exist in three different redox states: as the uncharged form (NO), as the nitrosoy anion (NO−) in the reduced state, and as the nitrosonium cation (NO+) in the oxidized state. They are mutually dependent and exchangeable. NO has unique pharmacokinetics as a potential therapeutic drug. It is small, gaseous and uncharged, and thus it can freely diffuse into tissues. However, the effects of NO are restricted locally due to its short half-life (approximately 1s) (Chiesa et al., 2018).

Because of the multiple roles of NO in pathophysiology, intense interest in the development of exogenous NO donor has been aroused. By modifying some functional groups in the molecule, different NO-donor compounds have been designed. Up to date, NO-donor compounds include diazeniumdiolates (NONOates), S-nitrosothiol, metal-nitrosyl, nitrobenzene, furoxans and
oxadiazoles (Zhou et al., 2016). NONOate is one of the most extensively studied NO-donor compounds. Their biomedical applications and developments have attracted wide attention in relevant field (Sharma et al., 2018). This review summarizes some advances in NONOates about pharmacokinetic characteristics, pharmacological effects, mechanisms and application prospects in recent years.

**DIAZENIUMDIOLATES**

Vascular endothelium is the main source of NO. The endothelial NO synthase (eNOS) regulates smooth muscle tone and platelet aggregation. The neuronal NO synthase (nNOS) generates NO in neuronal communication of cardiomyocytes regulating contractility. Both eNOS and nNOS are constitutively expressed generating basal NO concentration. The inducible NO synthase (iNOS) generates NO in macrophages, hepatocytes, and synoviocytes to regulate inflammation and immune functions. NONOate is considered as the effective substance for mimicking transient biosynthesis of NO, because its decomposition rate is mainly dependent on the amine component, pH and temperature. These different rates of NO generation make NONOates useful to mimic the low, transient NO synthesis by eNOS/nNOS.

NONOate is an optional, nucleophilic NO donor that offers many advantages as tools for probing the roles of NO in biological redox processes, especially in those physiological environment of requiring known, controllable rates of NO release. It is an exogenous NO donor agent with excellent performance developed in recent decades. NONOates are a series of compounds containing a X-[N(O)NO]− functional parent nuclear structural unit. X is a secondary amine. They are synthesized by the reaction of secondary amine with NO gas (Keefer, 2005; Sharma et al., 2018) and some of them have been commercially available. NONOates are convenient and uniquely advantageous NO dosage forms. They are stable in solids state. However, NONOate compounds can rapidly self decompose when dissolved in aqueous solution, activate the soluble guanylyl cyclase (sGC) system in organism to spontaneously generate up to two molecules of NO per [N(O)NO]− unit. When X = O−, first-order dissociation produces NO− rather than NO, but the ion becomes NO− source on 1-electron oxidation. NO derived from NONOate can also be used to generate reactive nitrogen/oxygen species with higher nitrogen oxidation states in the presence of selected oxidizing agents.

Interestingly, after the release of NO, there are no other metabolites produced except for the original amines. Since NONOate can produce different NO release rates and can be easily prepared into different physical states, there are local fast active drugs that can release NO completely within seconds, and long-term controlled-release drugs that need to be released for several hours. Therefore, NONOate is a kind of very important NO local release compounds. Researchers have developed NONOate macromolecule by developing amine-containing polymeric matrices to control the release of small molecule NONOates effectively (Zhang et al., 2019). These compounds have been widely explored in biomedical fields to show outstanding clinical application prospects. From the pharmaceutical point of view, it is very important that the design and modification of ionic NONOates can easily derive into other forms to deliver NO to the desired sites.

There are at least four characteristic advantages of NONOates, which make them the excellent agents in NO related research (Fitzhugh and Keefer, 2000). Firstly, NONOate have known rates of NO generation. NONOate are relatively stable in basic pH. They spontaneously decompose to generate 1–2 moles of NO per mole of donors with first order release kinetics in the presence of protons under physiological conditions. Secondly, the half-lives of NONOates exhibit a wide range with different chemical structures. The half-lives span ranges from 1.8 s (PROLI NONOate, at 37°C, pH 7.4) to 56 h (DETA NONOate, at 22–25°C, pH 7.4). Thirdly, NONOate spontaneously dissociate and release NO in solution. Most of them spontaneously split to release NO in a pH and temperature dependent manner, even without redox activation. Finally, three redox forms of NO can be present and exchangeable. Free radical (NO·) can be transformed into nitrosonium cation (NO+) or nitroxyl anion (HNO) by obtaining or losing an electron. Therefore, it is possible to use them as precursors of other NO donor compounds by activation and reaction. These attributes, such as namely structural diversity, dependable rates of NO release and a rich derivatization chemistry, make them designed to facilitate targeting of NO to specific need sites to solute the important clinical problems.

**REPRESENTATIVE DRUGS OF NONOATE AND CHARACTERISTICS**

NO inhibits platelet function and vasodilation. Hence, a majority of synthesized NO donor drugs are mainly used for treating cardiovascular diseases. The research intense in NO related drugs mainly focus on prodrugs, NO scavengers and inhibitors of endogenous NO synthesis. The goals of designing NO donor are to maximize the production of NO and to maintain the stability of drugs. Compared with other NO donors, NONOates don’t require redox activation. They can release NO at repeatable first-order rates in the aqueous solution. On the other hand, NONOates have the broad array of reproducible NO generation rates. These fundamental chemistry features set the NONOate ions apart as advantageous tools for investigating NO. The predictability of NONOate on the NO release rate and its compatibility with a variety of compounds make it gain more significant advantages than most of other NO donor agents. Therefore, NONOate derivatives are one of the most widely investigated NO donor compounds, which are mainly developed as NO donor and HNO donor prodrugs. Such NONOates as DEA NONOate, SP NONOate, and DETA NONOate are commercially available. The structure, half-life and characteristics of representative of NONOates are summarized and listed in Table 1. In the future, more researches about NONOate might focus on the field about its absorption through the skin and connection with polymer and plastic materials.
| Name | Molecular Formula | Molecular Weight | Half-life (t₁/₂) and Characteristics | Structure |
|------|-------------------|------------------|--------------------------------------|-----------|
| PROLI NONOate | C₈H₁₅N₃Na₂O₅ | 251.15 | Half-life = 1.8 s (at 37°C, pH 7.4) in aqueous solution, Dissociation is pH-dependent and first-order rates, which liberate 2 moles of NO/mole of PROLI NONOate. | ![Structure](image1) |
| MAHMA NONOate | C₂H₂₆N₄O₂ | 204.27 | Half-life = 1 minute (37°C, pH 7.4) and 3 min (22-25°C, pH 7.4) in aqueous solution, respectively. 2 moles of NO is liberated from 1 mole of MAHMA NONOate. | ![Structure](image2) |
| DEA NONOate | C₄H₁₀N₃NaO₂ | 155.13 | Half-life = 2 min (37°C, pH 7.4) and 16 min (22-25°C, pH 7.4), 1.5 moles of NO is liberated from 1 mole of DEA NONOate in aqueous solution. | ![Structure](image3) |
| PAPA NONOate | C₆H₁₆N₄O₂ | 176.22 | Half-life = 15 min (37°C, pH 7.4) and 77 min (22-25°C, pH 7.4) in aqueous solution. 1 mole of PAPA NONOate is dissociates to liberate 2 moles of NO. | ![Structure](image4) |
| DPTA NONOate | C₆H₁₇N₅O₂ | 191.23 | Half-life is about 3 h (37°C, pH 7.4) and 5 h (22-25°C, pH 7.4), pH 7.4, Dissociation is a pH-dependent, first-order process. 1 mole of DPTA NONOate is dissociates to liberate 2 moles of NO. | ![Structure](image5) |
| Spermine NONOate/SP NONOate | C₁₀H₂₆N₆O₂ | 262.35 | Half-life of is about 39 min (37°C, pH 7.4) and 230 min (22-25°C, pH 7.4), respectively, Dissociation is first-order rate and pH-dependent process. 1 mole of SP NONOate is dissociated to liberate 2 moles of NO. | ![Structure](image6) |
| DETA NONOate | C₄H₁₃N₅O₂ | 163.18 | Half-life of is about 20 h (37°C, pH 7.4) and 56 h (22-25°C, pH 7.4), respectively, 2 moles of NO is liberated from 1 mole of DETA NONOate. | ![Structure](image7) |
| β-Gal-NONOate | C₁₀H₁₉N₃O₇ | 293.27 | Half-life is about 6 min (pH 5.6), β-Gal-NONOate is stable at neutral for several h in aqueous solution and actived by β-galactosidase to release NO. | ![Structure](image8) |
| Sulpho NONOate | H₁₀N₄O₅S | 178.17 | Sulpho NONOate does not produce NO at physiological pH. Therefore, it usually may be used in the experiments about other NO-donor regents as a negative control. | ![Structure](image9) |
| IPA NONOate | Na[CH₃(2CHHNH(NO)NO] | 141.10 | Half-life is about 2 min in solution. At physiologic pH, HNO and NO is the main products released from the breakdown of IPA NONOate. The releasing level depends on the reaction conditions such as buffer pH and initial concentration of IPA NONOate. | ![Structure](image10) |

(Continued)
PHARMACOLOGICAL ACTIVITY AND DEVELOPMENT PROSPECT OF NONOATE

Effects on Cardiovascular System
In terms of cardiovascular system function, NO can relax vascular smooth muscle and inhibit platelet function. Therefore, NO related drugs, including NO donor prodrugs, NO scavengers and endogenous NO synthesis inhibitors, can be applied in the treatment of cardiovascular system diseases. Herein, we firstly review the pharmacological effects, mechanisms and application prospects of NONOates in cardiovascular diseases.

Vasorelaxation
NO is one of the most important vasodilator active substances in vivo. The vasodilator effect of NO donors provides a great potential for the treatment of such cardiovascular diseases as hypertension, angina pectoris and congestive heart failure. SP NONOates caused the expansion of femoral artery in rats by increasing the level of extracellular NO through the release after cleavage although its vasodilation is only partially mediated by soluble guanylate cyclase (sGC). It is suggested that the activity of NO and NO donors is not completely mediated by sGC (Miller et al., 2004). As an oral drug for the treatment of erectile dysfunction (ED), Sildenafil (Viagra) enhanced the vasodilatory effect of NO by specific inhibition of phosphodiesterase 5 (PDE5) to decrease the decomposition of cGMP. It is an oral drug for the treatment of erectile dysfunction (ED). SP NONOate is capable of potent relaxant action in the smooth muscle of penile cavernous body, which can be enhanced through oral sildenafil treatment. Therefore, SP NONOate is also considered as a potential drug for ED treatment (Ertug et al., 2014). Pinkney et al. demonstrated that IPA NONOate inhibited the hyperpolarization and contraction of arterial smooth muscles induced by phenylephrine, an α₁-adrenoceptor agonist, in a concentration dependent manner (Pinkney et al., 2017). Moreover, DETA NONOate could completely block the release of superoxide dismutase and the expression and activity of PDE5 protein in vascular smooth muscle cells (VSMCs). PDE5 could attenuate the vascular protection effect of NO through hydrolyzing cGMP (Muzaffar et al., 2008).

Reduction of Neointimal Hyperplasia and Atherosclerosis
As a one-electron reduction form of NO, HNO exhibited biological and pharmacological effects distinct from NO. IPA NONOate is a HNO donor at physiologic pH. IPA NONOate moderately inhibited intimal hyperplasia by reducing the proliferation of VSMCs and macrophage infiltration. In rat carotid artery injury model, IPA NONOate also inhibited endothelial cell proliferation (Tsihlis et al., 2010). In hypercholesterolemic mice, IPA NONOate presented both vasorelaxant effect and antiplatelet aggregation whereas the inhibitory effect of glyceryl trinitrate on platelet aggregation was abolished (Bullen et al., 2011).}

Vascular Protective Activity
The production of reactive oxygen species or superoxide anion is one of the pathogenic features of cardiovascular disease. NADPH oxidase can boost oxidative stress of vasculature in atherosclerosis. Excessive superoxide in arteries directly inactivates NO in endothelium and damages its vasoprotective effects. Selemidis found that the suppressive effect of some new NONOates on superoxide production was dependent on vascular NADPH oxidase making them more suitable for atherosclerosis therapy (Selemidis, 2008). Metal-NONOate Zn (PipNONO)Cl protected vascular endothelium by producing endogenous H2S and NO (Monti et al., 2018). DETA NONOate could completely block the release of superoxide dismutase and the expression and activity of PDE5 protein in vascular smooth muscle cells (VSMCs). PDE5 could attenuate the vascular protective effect of NO through hydrolyzing cGMP (Muzaffar et al., 2008).
significantly reduced (by 74%) in rabbits treated with SP NONOate in comparison with control animals after 14 days with SP NONOate treatment. Meanwhile, the treatment did not influence the blood pressure of mice. These results suggest that local administration of SP NONOate could effectively slow the development of neointima in this model (Yin and Dusting, 1997). Low concentrations of SP NONOate had minor inhibitory effect on low-density lipoprotein (LDL) oxidation while high concentration (> 4 mM) showed stronger inhibition. NO directly interacted with lipid peroxides (LPO) to form lipid nitroso adducts. This product could eliminate free LPO radicals and eliminate both free LPO radicals and the regeneration of LPO, thus preventing further aggravation and transition (Goss et al., 1995).

Therefore, as HNO/NO donor, the application and safety of IPA NONOate on cardiovascular diseases such as congestive heart failure (CHF) have been extensively conducted.

Inhibition of Platelet Function and Vasodilating Effects
NO is a physiological inhibitor of platelet aggregation. MAHMA NONOate inhibited the aggregation of collagen and ADP in platelet rich plasma (Homer and Wanstall, 2003). Low concentration of MAHMA NONOate activated the platelet inhibitory systems and decrease platelet aggregation in a cGMP dependent manner rapidly and transiently. This effect appeared to be cGMP independent at a high concentration (Kobsar et al., 2014). MAHMA NONOate inhibited the rat platelet aggregation by activation of sarco-endoplasmic reticulum calcium ATPase. This inhibitory effect was largely ODQ (a soluble guanylate cyclase inhibitor) resistant (Homer and Wanstall, 2002). The effect of MAHMA NONOate on platelet inhibition was approximately 10-fold more potent than S-nitrosglutathione (GSNO). It could also reduce systemic arterial pressure more than GSNO. Therefore, in vivo, MAHMA NONOate had platelet inhibition and vasodepressor effects (Homer and Wanstall, 2003).

Reduction in Pulmonary Hypertension
DETA NONOate attenuated pulmonary hypertension induced by group B Streptococcus. The vasodilating effect of DPTA NONOate in pulmonary vessels was more visible than that in systemic vessels (Dabrowska et al., 2005; Dabrowska et al., 2011). DEA NONOate relaxed the isolated rat small mesenteric artery by cGMP dependent/independent mechanisms (Turgut et al., 2013). SP NONOate relaxed rat pulmonary artery by producing cGMP, which could regulate the activation of Na⁺/K⁺-ATPase, Ca²⁺-ATPase and Ca²⁺-activated K⁺ channels (Homer and Wanstall, 2000). Jahidur Rashid et al. reported that a liposome was loaded both fasudil (a rho kinase inhibitor) and DETA NONOate to treat pulmonary hypertension (PAH). The results showed that the formulation of the liposome (loaded fasudil and DETA NONOate) could increase the level of cGMP in pulmonary artery muscle cells (SMCs) of PAH patients, which suggest that this combination therapy might be an effective treatment for PAH (Rashid et al., 2018).

Ant Cardiac Hypertrophy Effect
IPA NONOate inhibited the increase in cardiomyocyte size induced by endothelin-1 (ET1). IPA NONOate also alleviated myocardial hypertrophy induced by chronic pressure overload. The protective mechanism of IPA NONOate against cardiomyocyte hypertrophy was via HNO activation of cGMP signaling (Irvine et al., 2013).

Inhibition of Matrix Metalloproteinase-9-Dependent Remodeling on Vessel Wall
DETA NONOate administration increased NO concentration in rat aortic SMCs and explants. The expression of MMP-9 induced by IL-1β could be decreased by DETA-NONOate. In addition, there were no significant effects on the expression and activity of MMP-2 and tissue inhibitor of matrix metalloproteinas-1 in response to DETA NONOate treatment. These results indicate that DETA-NONOate may be helpful to inhibit the MMP-9-dependent vessel wall remodeling during abdominal aortic aneurysm formation (Sinha et al., 2006).

Angiogenesis
NO is an important angiogenic regulator. In angiogenic experiments and clinical research, compounds of NONOate subfamily have been used as tool agents. Majumder et al. reported that NO donors with different release patterns have different regulatory effects on angiogenesis, suggesting that SP NONOate had an unique NO release pattern which is most suitable for angiogenesis (Majumder et al., 2014). NO is necessary for arteriogenesis but iNOS also plays an important part. DETA NONOate potently stimulated the growth of collateral artery, activated perivascular monocytes, and increased the expression of proliferation markers in vessel cells. Shear stress-induced NO may activate the innate immune system and iNOS (Troidl et al., 2010). Metal-diazeniumdiolate complexes [{Cu (PipNONO)Cl} and {Ni(SalPipNONO)}] effectively induced vasorelaxation and endothelial cell proliferation (Ziche et al., 2008).

Although NO has a wide range of effects on cardiovascular diseases, some studies found that continuous low concentration inhalation of NO might produce a significant effect, and increasing NO concentration did not improve the clinical efficacy. Moreover, the high concentration of NO may be leading to cytotoxicity and DNA damage. Therefore, how to balance the clinical application of NO donor compounds and the discovery of novel compounds will be the key to NO donor drug research.

Effect on Nervous System
Neuroprotection
In the central nervous system, NO displays a series of functions, such as promoting the release of neurotransmitters, participating in the processes of synaptic plasticity and pain modulation, regulating the sleep wake cycle, etc. In the peripheral nervous system, NO is considered to be a neurotransmitter or mediator of non-cholinergic and non-adrenergic nerves, participating in the process of pain afferent and sensory transmission. Hua et al.
(2008) demonstrated that DETA NONOate reduced the hippocampal neurogenesis impairment induced by chronic mild stress (CMS) and reversed behavioral damage, suggesting that NONOate could be applied in the treatment of chronic stress depression by stimulating the neurogenesis of hippocampus tissue.

**Neurotoxicity**

Physiological amounts of NO are neuroprotective, whereas higher concentrations are clearly neurotoxic (Hua et al., 2008). NO will become noxious if it is excessively produced especially under redox reaction condition and toxic compounds reactive nitrogen species (RNS) will be formed to cause cell damage. In the development and progression of neurodegenerative disorders, NO and RNS demonstrate a pathogenetic effect (Balez and Ooi, 2016). NO has been considered as a part of the neurotoxic insult caused by neuroinflammation in the Alzheimer’s brain. However, this perception is changing due to recent researches in the early developments of Alzheimer’s disease, especially prior to the appearance of cognitive symptoms. NO could compensatorily protect synapses by increasing neuronal excitability. This neuroprotective mechanism of NO was via modulation of voltage-gated potassium channel activity (Hua et al., 2008).

**Anti-Oxidative Damage**

NO induced the function and expression of heme oxygenase-1 (HO-1), a key enzyme in cell stress response. NO is considered as an antioxidant and had a direct neuroprotective effect on oxidative damage. In addition, NO is involved in cell protection by activating sGC to increase cGMP concentration. DETA NONOate (1-10 mM) inhibited the neurotoxicity caused by H$_2$O$_2$ (20-100 mM) in 1-week-old rat cortical neurons (Fernandez-Tome et al., 1999).

**Reverse Activation of Inward Current in Neurones**

Thompson et al. (2009) demonstrated that DETA NONOate induced an inward current in cerebellar granule cells by directly activating cation selective channels through a whole cell patch clamp technique. However, GSNO, another NO donor, led to outward current generation in these cells. The interpretation and judgment of the results need further investigation when high concentrations of these NO donor compounds are used (Porshneva et al., 2018).

**Traumatic Brain Injury and Neurodegenerative Disorders**

In the rat model of traumatic brain injury (TBI) model rats, DETA NONOate significantly increased the survival, proliferation, differentiation and migration of neural progenitor cells in the injured cortex, hippocampus and other brain tissues. In addition, it improved the neurological function significantly. These results indicate that DETA NONOate has significant benefits for the treatment of TBI (Lu et al., 2003).

The role and application of NO donor compounds on the prevention of neurodegenerative diseases are still unclear. Because the drugs acting on the NO-cGMP pathway are able to counteract NO-induced damage, some scientists have proposed to use NO donor drugs to prevent or treat Alzheimer’s disease. However, the pharmacokinetic characteristics of these substances may limit their uses in neurodegenerative diseases so more research work will be required in the future.

**Anti Tumor Effects**

**Inhibition of Tumor Growth, Invasiveness, and Angiogenesis**

Although NO donors have been used for antitumor therapy, the effects of NO on growth and progression of tumors depends on its concentration. In 2006, Chen et al. (2006a) reported that β-Gal NONOate only released NO when hydrolyzed by induced β-galactosidase in 9L/LacZ cells, which led to its more powerful cytotoxicity than that of NONOate. However, in 9L cells, β-Gal NONOate showed less toxicity than NONOate. Therefore, β-Gal NONOate is a promising prodrug for targeting intracellular NO, which is expected to become a potential therapeutic drug for cancer ETA/NO dose- and time-dependently induced the cell viability of human endometrial tumors. The mechanism is activating caspase-3 and arresting cell cycle at the G0/G1 phase, associated with attenuating the expression of cyclin D1 and D3 (Waheed et al., 2019).

A metal-nonoate Ni(SalPipNONO) inhibited the cell proliferation and invasion of A549 cells (human lung carcinoma cells) to promote apoptosis. The antitumor activity of Ni(SalPipNONO) was more effective than that of DETA NONOate. The antitumor mechanism of Ni(SalPipNONO) was partly due to NO-cGMP dependent pathway, and partly to the salicylaldehyde moiety and ROS activated ERK1/2 signaling converging on p53 dependent caspase-3 cleavage. Furthermore, Ni(SalPipNONO) inhibited the angiogenesis of A549 cells, which was associated with reducing angiogenic factor expression and endothelial cell functions (Ciccone et al., 2018).

In general, these findings confirm that NO donor compounds produce its antitumor effect through a variety of mechanisms. NONOates can be further developed as a single agent or combination therapy.

**Synergistic Effect With Chemotherapy**

Treatment with NO donor enhanced the sensitivity of various tumors to chemotherapy, radiotherapy and immunotherapy. The potential mechanism of immune resistance in tumor is related to the anti proliferation and anti apoptosis pathways, as well as the increased expression of transcription factor Yin-Yang-1 (YY1) and programmed death ligand-1 (PD-L1). Overcoming these resistance mechanisms are needed to improve the sensitivity of anti-tumor therapy. NO donor decreased the expression of YY1 and PD-L1 by inhibiting the upstream NF-κB pathway. NO donor inhibited the S-nitrosylation of YY1 and then led to the inhibition of YY1 expression and the binding activity of YY1-DNA (Hays and Bonavida, 2019). β-Gal-NONOate enhanced the sensitivity of C6/lacZ, 9L/lacZ or HeLa/lacZ tumor cells to cisplatin, and reduced the dosage and side effects of cisplatin. Therefore, β-Gal-NONOate can be used as a chemosensitizer in tumor treatment with bright application (Deng et al., 2013).

As shown in above research, NONOates can exert the anti-tumor efficiency through multiple mechanisms and synergistic anti-tumor as a chemosensitizer, reduce or reverse drug resistance. Therefore, the development and research of NONOates has a good prospect as the novel antitumor agents.
Anti-Bacterial Effect
Bactericidal Activity
In the Escherichia coli transformed with lacZ gene, β-Gal-NONOate showed a stronger bactericidal effect than conventional NONOate. While, in the E. coli without lacZ gene, both β-Gal-NONOate and NONOate presented a low bactericidal activity. In the acute model of Pseudomonas aeruginosa (Pseudomonas aeruginosa) pneumonia, intermittent nebulization of DETA NONOate prolonged the continuous intrapulmonary delivery of NO and decreased the bacterial number in the lungs of model mice. However, there is no obvious influence on the infiltration of pulmonary leukocytes. Although the number of bacterial colonies was reduced after exposure to DETA NONOate in vitro, the antibacterial effect of NONOate was closely related with its nucleophilic backbone instead of NO. This finding indicates that the therapeutic effect of exogenous NO on P. aeruginosa pneumonia is limited (Dukelow et al., 2002).

Synergetic Antibacterial Effects
Bacterial biofilm is one of the important causes of bacterial resistance, chronic and recurrent infection. Rashin et al. (2018) reported that a novel NO-loaded polymer was synthesised. The NO-loaded polymer consisted of biocompatible oligoethylene glycol, hydrophobic ethylhexyl, cationic primary amine and NO donor. It exerted synergistic antibacterial effects through the eradication of biofilm mediated by NO and the disruption of P. aeruginosa cell membrane assisted by cationic polymer to induce bacterial death.

Other Effects
Acceleration of Wound Healing
NO plays a pivotal role in the cutaneous healing process. The topical supplement of NO is beneficial for wound healing. Zhang et al. reported a novel polyethylenimine (PEI) based NO donor polymer (PEI-PO-NONOate polymer), which presented high loading efficiency and controllable NO releasing curve and topical supplement of NO to promote wound healing. PEI-PO-NONOate polymer increased the formation of granulation tissue, collagen deposition and angiogenesis. Therefore, it has potential application prospects in accelerating the healing of cutaneous wound (Zhang et al., 2019).

Relieving of Ischemia/Reperfusion Injury in Transplanted Organs
Ischemia/reperfusion injury of transplanted organs may be associated with the loss of endothelial release of NO. Compared with control group, DEA NONOate significantly enhanced all hemodynamic parameters (12 h later) and aortic blood flow (6 h later). DEA NONOate treatment significantly improved coronary blood flow and cardiac function of rat isolated heart after 12 h of cryopreservation. These results indicate that the compounds have new applications in transplantation medicine (Kai et al., 2016).

Nonalcoholic Steatohepatitis
A variety of external or internal factors, such as inflammatory stimulation, oxidative stress and cytokines, could cause the activation of M1 macrophages in nonalcoholic steatohepatitis (NASH). Cytochrome P450 2E1 (CYP2E1) was closely associated with the polarization of M1 macrophages. Administration of NO donor DETA NONOate mechanistically inhibited CYP2E1 catalyzed the oxidative stress during the study in NASH-abrogated M1 polarization and NASH progression. This finding suggests that DETA NONOate is a promising strategy to the treatment of NASH (Seth et al., 2015).

Inhibition of Activation of Mast Cells
Exogenous NO had inhibitory action on human mast cells. IgE induced the release of histamin by mast cell. DEA NONOate dose-dependently inhibited histamine, eicosanoids and cytokines release induced by IgE. Regulation of NO by human mast cells was associated with the activation of the sGC-cGMP-PKG pathway and the inhibition of MAPK and NF kappaB phosphorylation (Yip et al., 2010).

Stimulation of Cl− Secretion by Airway Cells
Airway cells absorbed Na+ and secreted Cl− and bicarbonate ions via active transport mechanisms. The osmotic forces created by the coordinated transport of these ions are responsible for the movement of fluid across airways. NO stimulation of sGC was sufficient and necessary for increasing of short-circuit currents via stimulation of the apical cystic fibrosis transmembrane regulator (CFTR). Low concentration of NO donor DETA NONOate (1–1,000 µm) may help stimulate airway cells to secrete Cl−, but has no influence on alveolar edema (Chen et al., 2008).

Inhibition of Oxygen Consumption of Rat Leydig Cells In Vitro
NO plays an important role in the regulation of male reproductive system. NO and NOS regulated the secretion of androgen and sperm function. DPTA NONOate (10−3–10−6 M) inhibited oxygen consumption in isolated rat testis interstitial cells in a concentration dependent manner (Kojic et al., 2008).

Reducing Adhesions Formation in Rat Uterine Horn Model
Postsurgical adhesions occur following virtually all types of surgery, resulting in serious clinical complications. Endometrium adhesion is the most important cause of sterility. In rat uterine horn model, the adhesion formation at the site of peritoneal injury was significantly reduced by postoperative administration of N,O-carboxymethylchitosan and SP NONOate (Duran et al., 2003).

SUMMARY AND CONCLUSIONS
The finding of NO about the multiple physiological and pathophysiological functions has promoted a great number of pharmaceutical researches to develop NO-related agents for therapeutic purposes. In particular, NO-donors prodrugs may have some important therapeutic effects on such diseases as cardiovascular diseases (arterial hypertension, atherosclerosis, platelet aggregation, cardiac hypertrophy and male sexual impotence etc), nervous system diseases (traumatic brain injury, neurodegenerative disorders etc), tumor, bacterial infection
| Compound               | Pharmacological effect            | Mechanism                                                                 | Application prospect                  |
|------------------------|----------------------------------|---------------------------------------------------------------------------|--------------------------------------|
| DETA NONOate           | Vasorelaxation                   | Continuous and long-lasting NO production (Rahimi et al., 2011)            | Coronary artery bypass grafting      |
| DETA NONOate           | Vascular protection              | Blocks SOD release and PDE5 expression (Muzzaffar et al., 2008)            | Atherosclerosis                      |
| DETA NONOate           | Inhibition of MMP-9-dependent vessel wall remodeling | Decreases MMP-9 expression and activity induced by IL-1β (Sinha et al., 2006) | Abdominal aortic aneurysm formation |
| DETA NONOate           | Angiogenesis                     | Activates the innate immune system and activate inos (Troccoli et al., 2010) | Ischemic disease                     |
| DETA NONOate           | Neuroprotection                  | Activates Akt and cAMP-responsive CREB (Balez and Ooi, 2016)               | Nervous system injury                |
| DETA NONOate           | Neurotoxicity                    | Produces toxic compounds RNS (Balez and Ooi, 2016)                         | Neurodegenerative disorders          |
| DETA NONOate           | Anti-oxidative damage            | Activates soluble guanylate cyclase and increased cGMP concentrations (Fernandez-Torne et al., 1999) | Oxidative damage in cortical neurons |
| DETA NONOate           | Reverse activation of an inward current in neurons | Enhances the proliferation, differentiation and migration of neural progenitor cells of injured cortex (Ji et al., 2003) | Traumatic brain injury               |
| DETA NONOate           | Traumatic brain injury and neurodegenerative disorders | Decreases pulmonary bacterial load in mice with pneumonia (Dukelow et al., 2002) | Neurodegenerative disorders          |
| DETA NONOate           | Liver protection                 | Inhibition of CYP2E1-catalyzed oxidative stress (Seth et al., 2015)         | Nonalcoholic steatohepatitis         |
| DETA NONOate           | Antidepressant effect            | Reverses hippocampal neurogenesis impairment induced by CMS (Hua et al., 2008) | Depression                           |
| DETA NONOate           | Anti tumor effect                | Attenuates cyclin-D1 and D3 expression (Waeed et al., 2019)                | Endometrial tumors                   |
| DETA NONOate           | Stimulation of Cl⁻ secretion    | Stimulates sGC, resulting in increased cGMP levels and activation of PKGII, leading to phosphorylation and activation of CFTR (Chen et al., 2008) | Atherosclerosis                      |
| SP NONOate             | Slowing the development of neointima | Removes the lipid peroxyl radical but also abolish the regeneration of lipid hydroperoxide (Goets et al., 1995) | Atherosclerosis                      |
| SP NONOate             | Relaxant action in cavernous tissue | Relieving extracellular NO (Ertug et al., 2014)                             | Erectile dysfunction                 |
| SP NONOate             | Reduction in pulmonary hypertension | Producing cGMP to relax pulmonary artery (Homer and Wanstall, 2000)        | Pulmonary hypertension               |
| SP NONOate             | Anti tumor effect                | Increases NO sensitive sites in heparan sulfate and polyamine uptake (Cheng et al., 2009) | Cancer                               |
| SP NONOate             | Anti-inflammatory effect         | Reducing adhesions formation in rat uterine horn model (Duran et al., 2003) | Sterility                            |
| IPA NONOate            | Reduction of neointimal hyperplasia | Inhibits endothelial cell proliferation (Tahmis et al., 2010) and platelet aggregation (Bullen et al., 2011) | Atherosclerosis                      |
| IPA NONOate            | Anti cardiac hypertrophy effect  | Inhibited the increasing of cardiomyocyte size induced by ET1; HNO activated cGMP signaling (Irvin et al., 2013) | Myocardial hypertrophy               |
| DPTA NONOate           | Reduction in pulmonary hypertension | Produces cGMP, activated Na⁺/K⁺/ATPase, Ca²⁺-ATPase and Ca²⁺-activated K⁺ channels (Homer and Wanstall, 2000) | Pulmonary hypertension induced by group B Streptococcus | Tissue hypoxia; Sterility |
| DPTA/NO                | Inhibition of oxygen consumption | Inhibition of oxygen consumption of rat Leydig cells in vitro (Kojic et al., 2008) | Cancer                               |
| DEA NONOate            | Reduction in pulmonary hypertension | Relaxes isolated rat small mesenteric artery (Turgut et al., 2013)           | Pulmonary hypertension               |
| β-Gal-NONOate          | Anti tumor effect                | Inhibition of tumor growth, invasiveness and angiogenesis (Chen et al., 2006a) | Glioma                               |
| β-Gal-NONOate          | Bactericidal activity            | Decreases pulmonary bacterial load (Chen et al., 2006b)                    | E. Coli with transferred lac gene    |
| DEA NONOate            | Ischemia/reperfusion injury      | Improvement of coronary blood flow and heart function (Kai et al., 2016)     | Organ transplant                     |
| DEA NONOate            | Synergistic effect with chemotherapy | The activation of the sGC-cGMP-PKG pathway and the inhibition of MAPK and NF kappaB phosphorylation (Yip et al., 2010) | Drug resistance of tumor             |
| Gal-NONOate            | Synergistic effect with chemotherapy | Activates sarco-endoplasmic reticulum calcium ATPase (Homer and Wanstall, 2002) | Atherosclerosis                      |
| MAHMA NONOate          | Platelet inhibitory and vasodilator effects | Eradicates biofilm and disrupted bacterial membrane (Rashin et al., 2018) | Infectious disease                  |
| NONOate-based polymeric NO donors | Synergistic antibacterial effects | Produces endogenous H2S and NO and suppressed nadph oxidase dependent oxidative stress (Monti et al., 2018) | Atherosclerosis                      |
| Zn(PipPipNONO)Cl       | Vascular endothelium protective effect | Inhibits clonogenicity and cell invasion, promoted apoptosis (Ciccone et al., 2018) | Lung carcinoma                       |
| Ni(SalPipNONO)         | Anti tumor effect                | Enhances collagen deposition, granulation tissue formation, and angiogenesis (Zhang et al., 2019) | cutaneous wound healing              |
and inflammatory, immune or endocrine diseases. Intense pharmacological investigations in a series of NONOates are underway. Each NONOate has a specific pharmacokinetic and pharmacodynamic characteristic. The versatile roles of NONOate compounds, such as neuroprotective, cardioprotective, oncoprotective and immunoprotective agents, emphasize their important place in modern drug design and discovery. The effect, mechanism and application prospect of NONOates is summarized in Table 2. Although a growing number of novel NONOate compounds are synthesized and reported on their properties by different laboratories. Our view is that the clinical potential of NONOates should be maximized through a deeper and broader knowledge base is worth of engagement of more laboratories and scientists. In the future, this field might be needed much more efforts and imagination to explore the basic chemistry characteristics of the NONOate compounds to design and gain the more improved tools for chemical biology research, and important advances in medical engineering practice.

REFERENCES

Bahnson, E. S., Vavra, A. K., Flynn, M. E., Vercammen, J. M., Jiang, Q., Schwartz, A. R., et al. (2016). Long-term effect of PROLI/NO on cellular proliferation and phenotype after arterial injury. Free Radic. Biol. Med. 90, 272–286. doi: 10.1016/j.freeradbiomed.2015.11.027

Balez, R., and Ooi, L. (2016). Getting to NO Alzheimer’s Disease: Neuprotection versus Neurotoxicity Mediated by Nitric Oxide. Oxid. Med. Cell. Longev. 2016, 3806157. doi: 10.1155/2016/3806157

Bobko, A. A., and Khramtsov, V. V. (2014). Mechanistic studies of oxidative decomposition of Angeli’s salt and PAPA NONOate. Nitric Oxide 40, 99–98. doi: 10.1016/j.niox.2014.05.013

Bullen, M. L., Miller, A. A., Dharmarajah, J., Drummond, G. R., Sobey, C. G., and Kemp-Harper, B. K. (2011). Vasorelaxant and antaggregatory actions of the nitroxyl donor isopropylamine NONOate are maintained in hypercholesterolemia. Am. J. Physiol. Heart Circ. Physiol. 301, 1405–1414. doi: 10.1152/ajpheart.00489.2011

Chen, C., Shi, Y., Li, S., Qi, Q., Gu, L., Song, J., et al. (2006a). A glycosylated nitric oxide donor, beta-Gal-NONOate, and its site-specific antitumor activity. Arch. Pharm. (Weinheim) 339, 366–371. doi: 10.1002/ardp.200500262

Chen, C., Shi, Y. Q., Song, J., Qi, Q. S., Gu, L., and Wang, P. G. (2006b). Delivery of nitric oxide released from beta-Gal-NONOate activation by beta-galactosidase and its activity against Escherichia coli. Biol. Pharm. Bull. 29, 1239–1241. doi: 10.1248/bpb.b29.1239

Chen, L., Bosworth, C. A., Pico, T., Collawn, J. F., Varga, K., Gao, Z., et al. (2008). DETANO and nitrated lipids increase chloride secretion across lung airway cells. Am. J. Respir. Cell. Mol. Biol. 39, 150–162. doi: 10.1165/rcmb.2008–0005OC

Cheng, F., Johnsson, R., Nilsson, J., Fransson, L. A., Ellervik, U., and Mani, K. (2009). Potentiation of naphthoxylsido cytotoxicity on human tumor cells by difluoromethylrhodamine and spermine-NONOate. Cancer Lett. 273, 148–154. doi: 10.1016/j.canlet.2008.07.036

Chiesa, J. J., Baidanoff, F. M., and Golombok, D. A. (2018). Don’t just say no: Differential pathways and pharmacological responses to diverse nitric oxide donors. Biochem. Pharmacol. 156, 1–9. doi: 10.1016/j.bcp.2018.08.002

Cicone, V., Monti, M., Monzani, E., Casella, L., and Morbidelli, L. (2018). The metal-nonoate Ni(SalPpNONO) inhibits in vitro tumor growth, invasiveness and angiogenesis. Oncotarget 9, 13353–13365. doi: 10.18632/oncotarget.24350

Dabrowska, K., Hreh, D., Young, K. C., Navaretti, C., Ladino, J. F., Bancelari, E., et al. (2005). Effects of a nebulized NONOate, DPTA/NO, on group B streptococcus-induced pulmonary hypertension in newborn pigs. Pediatr. Res. 57, 378–383. doi: 10.1201/PDR.0000150802.35283.27

Dabrowska, K., Hreh, D., Ladino, J., Bancelari, E., and Suguhara, C. (2011). Effects of intermittent nebulization of NONOate, DPTA/NO, on group B Streptococccus-induced pulmonary hypertension in newborn pigs. Neonatology 99, 57–64. doi: 10.1159/000289286

Deng, L., Zhang, E., and Chen, C. (2013). Synergistic interaction of beta-galatosyl-pyrrolidin dialenuimidolate with cisplatin against three tumor cells. Arch. Pharm. Res. 36, 619–625. doi: 10.1007/s12272-013-0047-0

Dukelow, A. M., Weicker, S., Karachi, T. A., Razavi, H. M., McCormack, D. G., Joseph, M. G., et al. (2002). Effects of nebulized dithylenetetraamine NONOate in a mouse model of acute Pseudomonas aeruginosa pneumonia. Chest 122, 2127–2136. doi: 10.1378/chest.122.6.2127

Durán, B., Ak, D., Cetin, A., Guvenal, T., Cetin, M., and Imam, A. G. (2003). Reduction of postoperative adhesions by N-O-carboxymethylchitosan and spermine NONOate in rats. Exp. Anim. 52, 267–272. doi: 10.1538/expanimals.52.267

Ertug, F. P., Singirik, E., Buyuknacar, H. S., Gocmen, C., and Secilmis, M. A. (2014). Pharmacological profile of a nitric oxide donor spermine NONOate in the mouse corpus cavernosum. Turk. J. Med. Sci. 44, 569–575. doi: 10.3906/sag–1211-94

Fernandez-Tome, P., Lizasoain, L., Leza, J. C., Lorenzo, P., and Moro, M. A. (1999). Neuroprotective effects of DETA-NONOate, a nitric oxide donor, on hydrogen peroxide-induced neurotoxicity in cortical neurons. Neuroropharmacology 38, 1307–1315. doi: 10.1016/S0028-3908(99)00069-6

Fitzhugh, A. L., and Keefcr, L. K. (2000). Dizieniumidolates: pro- and antioxidant applications of the “NONOates”. Free Radic. Biol. Med. 28, 1463–1469. doi: 10.1016/S0891-5849(00)00251-3

Goss, S. P., Hogg, N., and Kalyanaraman, B. (1995). ox-LDLThe antioxidant effect and its activity against Streptococcus-induced pulmonary hy pertension in newborn piglets. Turk. J. Med. Sci. 35, 619–625. doi: 10.1016/s0028-3908(99)00069-6

Hays, E., and Bonavida, B. (2019). Nitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies. Antioxid. (Basel) 8, 407. doi: 10.3390/antiox8090407

Heckler, L., and Boon, E. M. (2019). Insights Into Nitric Oxide Modulated Quorum Sensing Pathways. Front. Microbiol. 10, 2174. doi: 10.3389/fmicb.2019.02174

AUTHOR CONTRIBUTIONS

All authors participated in collecting and discussing of literature data. BL and YM drafted the manuscript. YL andHX summarized and drew the tables. RF revised the spelling and grammar. ZL, RN, LL, DD, JX, CL, MX, and HS participated in data extraction. JC critically reviewed the review and made suggestions for improvements. All authors read and approved the final manuscript.

FUNDING

This study was supported by the financial support from National Science and Technology Major Project (Grant NO. 2018ZX09118109-005). We also gratefully acknowledge the financial support from Logistics Application Fundamental research key project (Grant NO. BWS17J031-08) and the Science and Health Joint Medical Research Project of Chongqing (Grant No. 2018MSXM002). We thank Mr. Yuanyuan Li for technical assistance.
Homer, K. L., and Wanstall, J. C. (2000). Cyclic GMP-independent relaxation of rat pulmonary artery by spermine NONOate, a diazeniumdiolate nitric oxide donor. *Nitric Oxide: Physiol. Pharmacol.* 3, 67–682. doi: 10.1006/n tooltip2.1999.0032

Homer, K. L., and Wanstall, J. C. (2002). Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate. *Br. J. Pharmacol.* 137, 1071–1081. doi: 10.1038/sj.bjp.0704971

Homer, K. L., and Wanstall, J. C. (2003). Platelet inhibitory effects of the nitric oxide donor drug MAHMA NONOate in vivo in rats. *Eur. J. Pharmacol.* 482, 265–270. doi: 10.1016/j.ejphar.2003.10.016

Hua, Y., Huang, X. Y., Zhou, L., Zhou, Q. G., Hu, Y., Luo, C. X., et al. (2008). DETA/NONOate, a nitric oxide donor, produces antipressor effects by promoting hippocampal neurogenesis. *Psychopharmacol. (Berl)* 200, 231–242. doi: 10.1007/s00213-008-1200-1

Irvine, J. C., Cao, N., Gossain, S., Alexander, A. E., Love, J. E., Qin, C., et al. (2013). Nitric Oxide-Loaded Antimicrobial Polymer for the Synergistic Eradication of Bacterial Biofilm. *ACS Macro Lett.* 7, 592–597. doi: 10.1021/acsmacrolett.8b00190

Rivera-Tirado, E., Lopez-Casillas, M., and Wesdemiotis, C. (2011). Characterization of diazeniumdiolate nitric oxide donors (NONOates) by electrospray ionization mass spectrometry. *Rapid. Commun. Mass Spectrom.* 25, 3588–3586. doi: 10.1002/rcm.5273

Solemidis, S. (2008). Suppressing NADPH oxidase-dependent oxidative stress in the vasculature with nitric oxide donors. *Clin. Exp. Pharmacol. Physiol.* 35, 1395–1401. doi: 10.1111/j.1440-1681.2008.05055.x

Seth, R. K., Das, S., Pourhoseini, S., Dattaroy, D., Igwe, S., Ray, J. B., et al. (2015). Mitochondrial nitric oxide enhances mitochondrial respiration and prevents oxidative damage in human podocytes. *J. Pharmacol. Exp. Ther.* 352, 77–89. doi: 10.1124/jpet.114.242026

Sharma, R., Joubert, J., and Malan, S. F. (2018). Recent Developments in Drug Design of NONOate Hybrid Compounds. *Mini. Rev. Med. Chem.* 18, 1175–1198. doi: 10.1016/j.mrc.2017.11.004

Sinha, I., Hannon, K. K., Ailawadi, G., Woodrum, D. T., Ford, J. W., Henke, P. K., et al. (2006). The nitric oxide donor NONOate decreases matrix metalloproteinase-9 expression and activity in rat aortic smooth muscle and abdominal aortic explants. *Ann. Vasc. Surg.* 20, 92–98. doi: 10.1016/j.avaux.2006.05.003

Stiller, F., Oliveira Formiga, R., Fernandes da Silva Coimbra, J., Alves-Filho, J. C., Cunha, T. M., and Cunha, F. Q. (2019). Targeting nitric oxide as a key modulator of sepsis, arthritis and pain. *Nitric Oxide* 89, 32–40. doi: 10.1016/j.niox.2019.04.011

Stroppel, A. S., Paolillo, M., Ziegler, T., Feil, R., and Stafforst, T. (2018). Npom-Protected NONOate Enables Light-Triggered NO/GMP Signalling in Primary Vascular Smooth Muscle Cells. *ChemBioChem* 19, 1312–1318. doi: 10.1002/cbic.201700683

Thompson, A. J., Mander, P. K., and Brown, G. C. (2009). The NO donor DETA-NONOate reversibly activates an inward current in neurones and is not mediated by the released nitric oxide. *Br. J. Pharmacol.* 158, 1338–1343. doi: 10.1111/j.1476-5381.2009.00400.x

Tsihlis, N. D., Murar, J., Kapadia, M. R., and Morbidelli, L. (2013). Cross-talk between endogenous H2S and NO accounts for vascular protective activity of the metal-nonoate Zn(PipNONO)Cl. *Biochem. Pharmacol.* 152, 143–152. doi: 10.1016/j.bcp.2013.08.025

Muzaffar, S., Shukla, N., Bond, M., Sala Newby, G. B., Newby, A. C., Angelini, G. D., et al. (2008). Superoxide from NADPH oxidase upregulates type 5 phosphodiesterase in human vascular smooth muscle cells: inhibition with iloprost and NONOate. *Br. J. Pharmacol.* 155, 847–856. doi: 10.1038/ bip.2008.300

Pinkney, A. M. H., Lemmy, H. A. L., Dora, K. A., and Garland, C. J. (2017). Vasorelaxation to the Nitroxyl Donor Isopropylamine NONOate in Resistance Arteries Does Not Require Perivascular Calcium In Gene-Related Peptide. *Hypertension* 70, 587–593. doi: 10.1161/HYPERTENSIONAHA.117.109737

Porshneva, K., Papiernak, D., Purski, M., Nowak, M., Matkowski, R., Eikert, M., et al. (2018). Combination Therapy with DETA/NO and Clodigopid Inhibits In metastasis in Murine Mammary Gland Cancer Models via Improved Vasoprotection. *Mol. Pharmacol.* 15, 5277–5290. doi: 10.1021/acs.molpharmaceut. 8b00781

Rahimi, N., Dehpour, A. R., Javadi-Paydar, M., Sohani, H., Rabbani, S., Ansari, M., et al. (2011). Effect of DETA-NONOate and papaverine on vasodilation of human internal mammary artery. *Can. J. Physiol. Pharmacol.* 89, 945–951. doi: 10.1139/h11-092

Rashid, J., Nahar, K., Raut, S., Keshavarz, A., and Ahsan, F. (2018). Fasudil and DETA NONOate, Loaded in a Peptide-Modified Liposomal Carrier, Slow PAH Progression upon Pulmonary Drug. *Mol. Pharm.* 15, 1755–1765. doi: 10.1021/acs.molpharmaceut.7b01003

Rashin, N.-Z., Zahra, S., Ali, B., Maeva, S.-N., Kitty, K. K. H., Naresh, K., et al. (2014). Nitric Oxide-Loaded Antimicrobial Polymer for the Synergistic Eradication of Bacterial Biofilm. *ACS Macro Lett.* 7, 592–597. doi: 10.1021/acsmaacrolett.8b00190

Selemidis, S. (2008). Suppressing NADPH oxidase-dependent oxidative stress in the vasculature with nitric oxide donors. *Clin. Exp. Pharmacol. Physiol.* 35, 1395–1401. doi: 10.1111/j.1440-1681.2008.05055.x
Zhang, Y., Tang, K., Chen, B., Zhou, S., Li, N., Liu, C., et al. (2019). A polyethylenimine-based diazeniumdiolate nitric oxide donor accelerates wound healing. Biomater. Sci. 7, 1607–1616. doi: 10.1039/C8BM01519H

Zhou, X., Zhang, J., Feng, G., Shen, J., Kong, D., and Zhao, Q. (2016). Nitric Oxide-Releasing Biomaterials for Biomedical Applications. Curr. Med. Chem. 23, 2579–2601. doi: 10.2174/0929867323666160729104647

Ziche, M., Donnini, S., Morbidelli, L., Monzani, E., Roncone, R., Gabbini, R., et al. (2008). Nitric oxide releasing metal-diazeniumdiolate complexes strongly induce vasorelaxation and endothelial cell proliferation. ChemMedChem 3, 1039–1047. doi: 10.1002/cmdc.200700354

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Li, Ming, Liu, Xing, Fu, Li, Ni, Li, Duan, Xu, Li, Xiang, Song and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.